Literature DB >> 16041382

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.

D G Brockstedt1, K S Bahjat, M A Giedlin, W Liu, M Leong, W Luckett, Y Gao, P Schnupf, D Kapadia, G Castro, J Y H Lim, A Sampson-Johannes, A A Herskovits, A Stassinopoulos, H G Archie Bouwer, J E Hearst, D A Portnoy, D N Cook, T W Dubensky.   

Abstract

We developed a new class of vaccines, based on killed but metabolically active (KBMA) bacteria, that simultaneously takes advantage of the potency of live vaccines and the safety of killed vaccines. We removed genes required for nucleotide excision repair (uvrAB), rendering microbial-based vaccines exquisitely sensitive to photochemical inactivation with psoralen and long-wavelength ultraviolet light. Colony formation of the nucleotide excision repair mutants was blocked by infrequent, randomly distributed psoralen crosslinks, but the bacterial population was able to express its genes, synthesize and secrete proteins. Using the intracellular pathogen Listeria monocytogenes as a model platform, recombinant psoralen-inactivated Lm DeltauvrAB vaccines induced potent CD4(+) and CD8(+) T-cell responses and protected mice against virus challenge in an infectious disease model and provided therapeutic benefit in a mouse cancer model. Microbial KBMA vaccines used either as a recombinant vaccine platform or as a modified form of the pathogen itself may have broad use for the treatment of infectious disease and cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041382     DOI: 10.1038/nm1276

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  56 in total

1.  T cell and APC dynamics in situ control the outcome of vaccination.

Authors:  Kamal M Khanna; David A Blair; Anthony T Vella; Stephen J McSorley; Sandip K Datta; Leo Lefrançois
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

2.  In vitro properties of a Listeria monocytogenes bacteriophage-resistant mutant predict its efficacy as a live oral vaccine strain.

Authors:  Patricia A Spears; M Mitsu Suyemoto; Terri S Hamrick; Rebecca L Wolf; Edward A Havell; Paul E Orndorff
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

3.  A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors:  Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-11-09       Impact factor: 3.641

4.  The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells.

Authors:  Matthew D Martin; Thomas C Wirth; Peter Lauer; John T Harty; Vladimir P Badovinac
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

5.  Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.

Authors:  Xinyan Zhao; Manxin Zhang; Zhongxia Li; Fred R Frankel
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 6.  Clinical development of Listeria monocytogenes-based immunotherapies.

Authors:  Dung T Le; Thomas W Dubenksy; Dirk G Brockstedt
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 7.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

Review 8.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 9.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

10.  A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; David Laurin; Caroline Aspord; Julien Verove; Yan Wang; Charlotte Genestet; Candice Trocme; Mitra Ahmadi; Sandrine Martin; Alexis Broisat; François Cretin; Catherine Ghezzi; Benoit Polack; Joël Plumas; Bertrand Toussaint
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.